Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor adverse events and low-response study in hypercholesterolemic adults
NL-OMON55799Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of alirocumab and evolocumab in hypercholesterolemia (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Differences in clinical parameters, PCSK9 gene mutations and 4 more. Started Nov 2018; status: active, not recruiting.
02
Drugs
alirocumabevolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON55799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55799.